NCT03600831View on ClinicalTrials.gov

Postoperative Concurrent Chemoradiotherapy Versus Radiotherapy Alone for Patients With Locoregionally Advanced Esophageal Squamous Cell Carcinoma

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

434

Participants

Timeline

Start Date

August 20, 2018

Primary Completion Date

May 30, 2022

Study Completion Date

December 31, 2023

Conditions
Esophageal Squamous Cell Carcinoma
Interventions
DRUG

Docetaxel plus cisplatin

cisplatin 25mg/m2 on day 1 and docetaxel 25mg/m2 on day 1 weekly for 5 weeks

RADIATION

radiotherapy

radiotherapy: 50Gy (2.0 Gy/fraction, 5 days a week)

Trial Locations (4)

211700

xuyi peiple's Hospital, Xucheng

223300

Chinese Peiple's Liberation Army No.82 Hospital, Huai'an

Huai'an second peiple's Hospital, Huai'an

Lianshui County Peoples Hospital, Huai'an

All Listed Sponsors
collaborator

The Second People's Hospital of Huai'an

OTHER

collaborator

lian shui county People's Hospital

UNKNOWN

collaborator

xuyi People's Hospital

UNKNOWN

collaborator

Chinese People's Liberation Army No. 82 Hospital

UNKNOWN

lead

Huai'an First People's Hospital

OTHER

NCT03600831 - Postoperative Concurrent Chemoradiotherapy Versus Radiotherapy Alone for Patients With Locoregionally Advanced Esophageal Squamous Cell Carcinoma | Biotech Hunter | Biotech Hunter